Literature DB >> 12839972

Regulation of multiple tumor microenvironment markers by overexpression of single or paired combinations of ErbB receptors.

Moulay A Alaoui-Jamali1, Daniel J Song, Naciba Benlimame, Lily Yen, Xiaoming Deng, Maite Hernandez-Perez, Taiqi Wang.   

Abstract

The progression of primary tumors to an invasive phenotype requires dynamic changes in multiple cellular and local tumor microenvironment markers. In this study, we report a genomic approach to assess gene transcriptional changes upon overexpression of ErbB receptors, in vitro and in vivo, focusing on markers involved in the regulation of the tumor microenvironment. ErbB receptors (ErbB-1/epidermal growth factor receptor, ErbB-2, ErbB-3, and ErbB-4) were stably overexpressed in a polyclonal cell population as single or paired combinations using murine and human breast cell models. The overall numbers of known genes that are up- or down-regulated was significantly higher in cells and tumors overexpressing paired combinations of receptors compared with cells and tumors overexpressing single ErbB receptors. Genes encoding components of cell-cell structures, extracellular matrix, coagulation factors, and angiogenesis were predominantly affected by the most active ErbB receptor combinations and were predictive of the aggressive in vivo tumorigenicity, a feature that was not always seen in vitro. Among ErbB-regulated tumor microenvironment markers detected by the genomic analysis, thrombospondin 1, an endogenous inhibitor of angiogenesis, was additionally validated in relation to tumor growth phenotype. Thrombospondin 1 mRNA and protein were down-regulated by specific ErbB receptors, in vitro and in both rodent and human ErbB-induced tumors, consistent with the extent of tumor growth and tumor vascularization associated with specific ErbB receptors. In summary, our genomic results highlight the broad diversity of ErbB-regulated cancer-associated genes and revealed several novel targets that may have potential therapeutic applications for targeting tumor progression involving aberrations of ErbB receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12839972

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Regulation of early Xenopus development by ErbB signaling.

Authors:  Shuyi Nie; Chenbei Chang
Journal:  Dev Dyn       Date:  2006-02       Impact factor: 3.780

2.  Cooverexpression of ERBB1 and ERBB4 receptors predicts poor clinical outcome in pN+ oral squamous cell carcinoma with extranodal spread.

Authors:  Sabrina Daniela Silva; Moulay A Alaoui-Jamali; Michael Hier; Fernando Augusto Soares; Edgard Graner; Luiz Paulo Kowalski
Journal:  Clin Exp Metastasis       Date:  2013-12-15       Impact factor: 5.150

3.  Epidermal growth factor receptor stimulation activates the RNA binding protein CUG-BP1 and increases expression of C/EBPbeta-LIP in mammary epithelial cells.

Authors:  Brenda R Baldwin; Nikolai A Timchenko; Cynthia A Zahnow
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

Review 4.  Role of ErbB4 in breast cancer.

Authors:  Maria Sundvall; Kristiina Iljin; Sami Kilpinen; Henri Sara; Olli-Pekka Kallioniemi; Klaus Elenius
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-05-03       Impact factor: 2.673

5.  Janus kinase 2 is required for the initiation but not maintenance of prolactin-induced mammary cancer.

Authors:  K Sakamoto; A A Triplett; L A Schuler; K-U Wagner
Journal:  Oncogene       Date:  2010-07-19       Impact factor: 9.867

6.  Cell death or survival promoted by alternative isoforms of ErbB4.

Authors:  Maria Sundvall; Ville Veikkolainen; Kari Kurppa; Zaidoun Salah; Denis Tvorogov; E Joop van Zoelen; Rami Aqeilan; Klaus Elenius
Journal:  Mol Biol Cell       Date:  2010-10-13       Impact factor: 4.138

Review 7.  CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases.

Authors:  Cynthia A Zahnow
Journal:  Expert Rev Mol Med       Date:  2009-04-08       Impact factor: 5.600

Review 8.  Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinoma.

Authors:  Alphonse-E Sirica
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

Review 9.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

10.  Quantitative proteomics analysis of the effects of ionizing radiation in wild type and p53 K317R knock-in mouse thymocytes.

Authors:  Lisa M Miller Jenkins; Sharlyn J Mazur; Matteo Rossi; Olga Gaidarenko; Yang Xu; Ettore Appella
Journal:  Mol Cell Proteomics       Date:  2008-01-04       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.